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Abstract: Purpose:  An appropriate healthy control dataset is mandatory to achieve good
performance in voxel-wise analyses. We aimed at evaluating [18F]FDG PET brain
datasets of healthy controls (HC), based on publicly available data, for the extraction of
voxel-based brain metabolism maps at the single-subject level.
Methods:  Selection of HC images was based on visual rating, after Cook’s distance
and Jack-knife analyses, to exclude artefacts and/or outliers. The performance of these
HC datasets (ADNI-HC and AIMN-HC) to extract hypometabolism patterns in single
patients was tested in comparison with the standard reference HC dataset (HSR-HC)
by means of Dice score analysis. We evaluated the performance and comparability of
the different HC datasets in the assessment of single-subject SPM-based
hypometabolism in three independent cohorts of patients, namely ADD, bvFTD and
DLB.
Results:  Two-steps Cook’s distance analysis and the subsequent Jack-knife analysis
resulted in the selection of n=125 subjects from the AIMN-HC dataset and n=75
subjects from the ADNI-HC dataset. The average concordance between SPM
hypometabolism t-maps in the three patient cohorts, as obtained with the new datasets
and compared to the HSR-HC standard reference dataset, was 0.87 for the AIMN-HC
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dataset and 0.83 for the ADNI-HC dataset. Pattern expression analysis revealed high
overall accuracy (>80%) of the SPM t-map classification according to different
statistical thresholds and sample sizes.
Conclusions:  The applied procedures ensure validity of these HC datasets for the
single-subject estimation of brain metabolism using voxel-wise comparisons. These
well-selected HC datasets are ready-to-use in research and clinical settings.
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Purpose: An appropriate healthy control dataset is mandatory to achieve good performance in voxel-wise 
analyses. We aimed at evaluating [18F]FDG PET brain datasets of healthy controls (HC), based on publicly 
available data, for the extraction of voxel-based brain metabolism maps at the single-subject level.  
Methods: Selection of HC images was based on visual rating, after Cook’s distance and Jack-knife analyses, 
to exclude artefacts and/or outliers. The performance of these HC datasets (ADNI-HC and AIMN-HC) to 
extract hypometabolism patterns in single patients was tested in comparison with the standard reference HC 
dataset (HSR-HC) by means of Dice score analysis. We evaluated the performance and comparability of the 
different HC datasets in the assessment of single-subject SPM-based hypometabolism in three independent 
cohorts of patients, namely ADD, bvFTD and DLB. 
Results: Two-steps Cook’s distance analysis and the subsequent Jack-knife analysis resulted in the selection 
of n=125 subjects from the AIMN-HC dataset and n=75 subjects from the ADNI-HC dataset. The average 
concordance between SPM hypometabolism t-maps in the three patient cohorts, as obtained with the new 
datasets and compared to the HSR-HC standard reference dataset, was 0.87 for the AIMN-HC dataset and 0.83 
for the ADNI-HC dataset. Pattern expression analysis revealed high overall accuracy (>80%) of the SPM t-
map classification according to different statistical thresholds and sample sizes. 
Conclusions: The applied procedures ensure validity of these HC datasets for the single-subject estimation of 
brain metabolism using voxel-wise comparisons. These well-selected HC datasets are ready-to-use in research 
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[18F]Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG PET) is the most widely used tool for 
the in vivo measurement of brain metabolism, a crucial biomarker in dementia as a proxy for synaptic 
dysfunction and neurodegeneration [1]. Disease-specific hypometabolism patterns, obtained with [18F]FDG 
PET imaging, provide support to the early and differential diagnosis of several neurodegenerative conditions 
[2,3]. 
Metrics for [18F]FDG PET imaging hold substantial value to estimate the extent of brain metabolic 
derangement in neurodegenerative conditions (ND), providing distinctive metabolic patterns that increase 
diagnostic accuracy, even in the prodromal disease phase  [2,4]. Multiple studies have reported indeed high 
sensitivity and specificity in studies adopting appropriate metrics for [18F]FDG PET;. overall, good quality of 
evidence exists in early and differential diagnosis of ND dementia. Crucially, highly accurate, reliable, and 
reproducible measures of neurodegeneration are essential for inclusion in therapeutic trials and for treatment 
evaluation and monitoring.   
While the use of [18F]FDG PET is recommended by several clinical/research diagnostic criteria [5–11], in 
2015, a Cochrane review questioned the diagnostic and prognostic accuracy of [18F]FDG PET in early 
prodromal phases of dementia [12]. The imminent reply of the European Association of Nuclear Medicine 
(EANM) [13] objected such conclusion, on the grounds that it was mostly based on studies with evaluation of 
[18F]FDG PET images limited to the visual inspection of radiotracer distribution, thus neglecting the objective 
measures as a major bias. The implementation of standardized [18F]FDG PET readouts and operator-
independent maps were strongly advocated by both the United States Society of Nuclear Medicine and the 
Molecular Imaging and the European Association of Nuclear Medicine [13,14].    
Different advanced parametric tools, each including a HC database for statistical comparison, have been 
introduced so far. These tools can be subdivided into those that were developed for commercial/clinical use, 
which are the majority, e.g. CortexID (GE), Neurocloud-PET (Qubiotech Health Intelligence) 
(www.neurocloud.es), MIMNeuro (MIM Software), NeuroQTM (Syntermed), Syngo.PET (Siemens) and Brass 
(Hermes Medical Solutions, PNEURO/PALZ (PMOD Technologies), and those that were developed for 
research purposes, e.g. NeuroSTAT and PETQuant (Cortechs Lab). In this context, indices providing a single 
measurement of the expression of hypometabolism patterns, such as the Hypometabolic Convergence Index, 
or the ADNI metaROI, are also available [15,16].    Of note, even when objective measurements are applied, 
based on the available tools, results may vary depending on the tool characteristics. One must also be aware 
of the lack of validation and standardization, for example with respect to the selected intensity normalization 
methods, or to differences amongst scanners and centers in the acquisition procedures [17]. In general, head-
to-head comparisons are still required to harmonize quantification procedures; so far, the complexity of the 
current quantification tools, especially those developed for research uses, represents a limitation for  the routine 




































































Crucially, the selection criteria applied for the inclusion of normal subjects within each software are often not 
described in detail, nor published in the literature. The selection of the healthy controls (HC), i.e. classified as 
cognitively healthy at the time of the scan, in these tools, is often based on the availability of [18F]FDG PET 
only, and does not take into account eventual patterns of neurodegeneration at the [18F]FDG PET scan, nor 
the presence of brain pathology at CT or MRI, and crucially the cognitive and clinical trajectories of each 
included subject. As an example, in the Hypometabolic Convergence Index, 47 healthy controls from the 
ADNI database were used for comparison, of which four had converted to MCI after the baseline scan, one at 
month 6 (who turned to Alzheimer’s disease dementia at month 36) and three at month 24 [15]. An appropriate 
healthy control dataset is mandatory to obtain a good performance in voxel-wise analyses. Criteria for clinical 
normality are usually based on the absence of cognitive impairments, neurological or psychiatric diseases and 
the use of structured interviews. Furthermore, for better quality results, HC selected for comparisons should 
be followed up longitudinally to confirm long lasting cognitive stability. It has been shown that using a control 
group of subjects followed longitudinally for 4 years (instead of mixed databases) strongly increases the 
accuracy (1.4- to 2-fold) of disease detection in an automated [18F]FDG PET analysis [19]. 
In this work, we aimed to provide a validation of two [18F]FDG PET databases of publicly available, clinically 
well-characterized samples of HC to the research and clinical communities. These normative datasets can be 
used by applying several statistical approaches, such as t-test in the SPM toolbox or others.  
Currently, SPM does not provide a normal dataset to perform brain [18F]FDG PET voxel-wise statistical 
analyses.  Here, we showed an application of SPM procedures that are freely downloadable from the web. 
Notably, while the earliest versions needed a MATLAB® platform, the most recent standalone version does 
not. Our group has previously validated  this  semi-quantitative optimized method based on SPM [20,21]. It 
includes a spatial normalization based on a [18F]FDG PET dementia-specific template (freely available at 
http://inlab.ibfm.cnr.it/inlab/PET_template.php) [22], that improves the detection of subtle metabolic 
abnormalities associated with specific cognitive impairment and the recognition of different patterns of 
neurodegeneration – particularly in early disease stages. The procedure is based on a large healthy subjects 
dataset of [18F]FDG PET images for statistical comparison (n=112) belonging to a San Raffaele Hospital 
internal dataset [20,22]. This method showed very high accuracy for differential diagnosis of ND dementia, 
atypical parkinsonian disorders, and crucially for prognosis in the risk assessment of progression in the 
prodromal phase of mild cognitive impairment [2,3]. Here, after implementing an analytical pipeline to build 
up the appropriate HC datasets, we investigated the robustness of the SPM t-maps obtained with the two new 
well-selected HC datasets, both based on publicly available data provided by the Italian national association 
of nuclear medicine (AIMN) and from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), respectively. 
By using these datasets, SPM hypometabolism t-maps were extracted from three different clinical groups, 
namely patients affected by Alzheimer’s disease dementia (ADD), dementia with Lewy body (DLB) and the 
behavioural variant of frontotemporal dementia (bvFTD). Notably, we also investigated the impact of the size 
of the control dataset on the resulting single-subject SPM t-maps, at  different statistical thresholds, so as to 




































































We would like to promote the use of semi-quantitative objective measures of brain metabolism by means of 
statistical comparisons with these normative datasets for an accurate assessments of brain metabolism in 
research and clinical settings.    
 
Materials and Methods 
HC datasets 
We considered two HC [18F]FDG PET datasets, one obtained from the AIMN website (aimn.it) and one from 
the ADNI website (adni.loni.usc.edu).  
The AIMN is a voluntary non-profit association, whose purpose is to promote the application and development 
of the medical and biological use of the physical properties of the atomic nucleus. The AIMN represents the 
Italian scientific reference for Nuclear Medicine and Molecular Imaging activities. Qualified members of 
AIMN can submit an online request to obtain [18F]FDG PET images from HC subjects acquired by different 
Italian Nuclear Medicine Units . We downloaded n=187 [18F]FDG PET scans, i.e. all the images available on 
the AIMN database (https://www.aimn.it/site/page/gds/gds-5). This database comprised subjects aged between 
20 and 84 years (mean: 61.88±13.69). These subjects were selected because they were characterized by 
absence of global cognitive impairment, as assessed by a MMSE score ≥ 28, and were cognitively normal after 
an average 4-year clinical follow-up.    
The ADNI is an American public-private partnership launched in 2003 led by Principal Investigator Michael 
W. Weiner, MD to collect longitudinal data on MCI and ADD patients as well as on healthy subjects. The 
primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other 
biological markers, and clinical and neuropsychological assessment can be combined to measure the 
progression of MCI and early ADD (see www.adni-info.org for more information). All data generated by the 
ADNI study investigators are entered in the data repository hosted at the Laboratory of Neuroimaging (LONI) 
at the University of Southern California, the LONI Image & Data Archive (IDA). Qualified researchers 
worldwide can submit an online data access request and begin using ADNI data including 
cognitive/neuropsychological, image, biofluid and genetic data sets within a few days from request submission. 
The ADNI data repository contains more than 500 healthy control subjects acquired with [18F]FDG PET. 
Among them, we selected n=101 subjects (age range: 56-94 years; mean: 73.49±6.97). These subjects were 
selected because they were characterized by absence of global cognitive impairment, as assessed by a MMSE 
score ≥ 28, and were cognitively normal after an average 4-year clinical follow-up.  Moreover, subjects 
showing amyloid PET positivity were excluded from the analysis. Amyloid PET positivity was established 
based on quantitative assessment of global signal uptake value ratio (SUVr), as provided by ADNI. Details on 
such procedures are described in the ADNI analytical pipelines (http://adni.loni.usc.edu/).  
Presence of significant amyloid-β burden (amyloid-positivity) was established based on quantitative 




































































Presence of significant amyloid-β burden (amyloid-positivity) was established based on a validated cut-off of 
1.5 SUVr for [11C]PiB-PET scans and of 1.11 SUVr for [18F]Florbetapir-PET scans, as derived from large 
studies in healthy controls. Further details are described in the ADNI analytical pipelines 
(http://adni.loni.usc.edu/). 
Overall, these selection procedures allowed us to exclude, with higherconfidence, HC subjects who might be 
on a trajectory towards mild cognitive impairment or dementia.  
HSR-HC reference dataset – A group of 112 healthy control [18F]FDG PET scans was here included as 
reference standard. The HSR-HC dataset was previously developed and validated by our group for the 
extraction of hypometabolism maps in individual neurological patients, or groups (see section “SPM t-maps 
extraction in dementia conditions”). This represents the internal HC database at San Raffaele Hospital (HSR) 
Nuclear Medicine Unit, which is largely used for research purposes and in support to clinical routine 
[20,21,23–27].  
 
Patient groups datasets 
From a large clinical cohort referred to the Departments of Neurology and Nuclear Medicine Unit of San 
Raffaele Hospital (Milan, Italy), we retrospectively selected the patients who underwent [18F]FDG PET scans 
and received a diagnosis of probable dementia, namely 79 cases diagnosed with probable ADD [11], 81 with 
probable DLB [5], and 56 fulfilling current clinical criteria for bvFTD [10]. All patients had a confirmed 
neurological diagnosis after at least 5-year follow-up.   These groups of patients were included in order to 
compare the results of the SPM procedure using the different HC datasets for the extraction of single-subject 
hypometabolism maps. 
All subjects and/or authorized representatives provided written informed consent, following detailed 
explanation of each experimental procedure. ADNI subjects gave written informed consent at the time of 
enrolment for data collection and completed questionnaires approved by each participating sites Institutional 
Review Board. The protocols conformed to the ethical standards of the Declaration of Helsinki for protection 
of human subjects. 
[18F]FDG PET Scanning Procedures and Pre-processing 
AIMN and HSR scanning procedures- An [18F]FDG PET brain study was performed in all subjects (healthy 
controls and patients) according to the conventional neurological acquisition protocols and to the European 
Association of Nuclear Medicine (EANM) guidelines [28]. Before radiopharmaceutical injection, subjects 
were fasted for at least six hours to ensure that the measured blood glucose level was <120 mg/dL. Subjects 
underwent a 3D PET scan (time interval between injection and scan start ranged from 30 to 45 min; scan 




































































[18F]FDG (185–250 MBq: usually, 5–8 mCi via a venous cannula). Images were reconstructed using an 
ordered subset expectation maximization algorithm. 
[18F]FDG PET images belonging to AIMN subjects were obtained using either a PET/CT system GE 
Discovery STE, GE Discovery 710, or Siemens Biograph 16 scanner. [18F]FDG PET images belonging to 
HSR subjects were obtained using a either a GE Discovery ST, GE Discovery STE, Siemens Biograph Hi-rez 
or Siemens ECAT EXACT HR+ PET scanner. 
ADNI PET Scanning procedures - A list of PET and PET/CT scanners used in ADNI centres is available 
elsewhere (http://adni.loni.usc.edu). ADNI acquisition procedures are comparable to those described above, 
with acquisitions starting 30 minutes post injection, and six 5-minute frame being acquired for the next 30 
minutes.  As for the [18F]FDG PET images included, only the last three 5-minute frames were retrieved from 
the ADNI database and combined to obtain a single 15-min static image. In such way, we ensured uniform 
acquisition procedures for all [18F]FDG PET images, independently of the acquisition site. Assuming the 
image reconstruction algorithm is unbiased, summing dynamic frames gives identical results as performing a 
static acquisition of the same time length. It also allows to correct for inter-frame motion. Even in case of 
statistical reconstruction algorithms, small bias has been reported exclusively in “cold structures” and for very 
short frames (less than 10 seconds) [29].  
ADNI acquisition procedures are detailed elsewhere (http://adni.loni.usc.edu/data-samples/data-types/pet/). 
[18F]FDG-PET images belonging to ADNI subjects were obtained using ECAT HR+, General Electric 
Discovery LS, General Electric Discovery ST, General Electric Discovery STE, Siemens/ECAT HRRT, 
Siemens Biograph Hi-Rez, Philiphs Gemini TF, Siemens mCT, ECAT Biograph. 
Pre-processing – A visual quality check of the images was performed to identify potential artefacts (e.g. 
acquisition issues, excessive patient motion) and issues related to technical characteristics, such as the use of 
compatible reconstruction algorithms. Then, [18F]FDG PET images of patients and controls were normalized 
to the optimized [18F]FDG PET template [21], using SPM12 (https://www.fil.ion.ucl.ac.uk/spm/). They were 
then scaled to the global mean of the activity within the brain [30] and finally smoothed with an isotropic 3D 
Gaussian kernel (8 mm FWHM), accordingly with the validated pipeline proposed for our single-subject SPM-
based analysis [20,22]. This kind of smoothing is required for the random field theory to be applicable. It is 
also effective in reducing the number of multiple comparisons to be performed [31].  
HC datasets processing  
Study design – The validation of the HC groups was performed following two main steps. In the first step, we 
performed a quantitative outliers detection by means of “Cook’s distance analysis” [22]. In the second step, 
we optimized outlier detection by classifying SPM t-maps extracted by means of a jack-knife approach, where 
every normalized HC scan was evaluated with respect to the remaining sample of HC (AIMN-HC or ADNI-
HC) via a two-sample t-test in SPM12. The resulting SPM t-maps were visually inspected by two neuroimaging 




































































Cook’s distance analysis - In order to detect outliers and to remove them from the two HC datasets (AIMN 
and ADNI), we measured the Cook’s distance for each subject.  







Where 𝑦?̂? is the predicted model response for subject 𝑗, and 𝑦𝑖(𝑗)^  the estimated response when the model is 
estimated without subject 𝑖, 𝑝 the number of covariates and 𝑠 the mean squared error of the regression model. 
In this case, 𝑦?̂? are images and their squared difference is computed as the Euclidian distance.  
Thus, we obtained a Cook’s distance value for each analysed subject. The Cook’s distance values were 
averaged over all the voxels that are included in the SPM analysis, and then plotted in order to define the 
critical D value. We considered the “elbow” on the arm of the distribution, as representing the best critical D 
value. A Cook’s distance below the critical D value is expected not to have any large impact on sample 
distribution. Thus, the subject can be considered representative of the group and can be included in the HC 
sample. Instead, a Cook’s distance above the critical D value indicates that the subject has a disproportionate 
impact on the estimated general linear model.  
We computed Cook’s distance twice for each HC group (AIMN or ADNI HC groups): first, in the whole HC 
group, in order to exclude the most egregious outliers; second, we re-computed Cook’s distance by using only 
the subjects that survived to the first step. We obtained two new HC groups, which were than further analysed 
in the following step.  
Jack-knife approach – The SPM statistical voxel-wise procedure consists in a t-test, in which a single 
individual is compared with a dataset of HC, entering age as a covariate. This statistical comparison provides 
t-scores for each brain voxel [20]. In this case, every normalized [18F]FDG PET images was evaluated with 
respect to the remaining sample via a two-sample t-test so that a SPM t-map is obtained for each HC subject 
(jack-knife approach). SPM t-maps were generated from this statistical comparison in order to identify  
eventual brain areas of significant hypometabolism (p<0.05). Only clusters containing more than 100 voxels 
were considered to be significant [20]. Two neuroimaging experts visually inspected all the SPM t-maps in 
order to confirm the scan negativity, namely the absence of hypometabolism patterns compatible with 
neurodegenerative processes. 
All the above analyses allowed to obtain HC groups without outliers.  
Validation of HC datasets for t-maps extraction in dementia conditions  
SPM single-subject standardized procedure - We tested for the validity of the two new selected HC datasets 
(AIMN-HC and ADNI-HC) in extracting single-subject hypometabolism t-maps in three different group of 
patients, namely ADD, DLB and bvFTD.  To do so, we ran our standardized SPM procedure [20] on the three 




































































comparison, the second time with the AIMN-HC dataset and the third time with the ADNI-HC dataset. The p-
value of the single-subject hypometabolism maps was set at p<0.05 uncorrected, with a cluster-forming 
threshold of n = 100 voxels [20]. We selected images regardless of the scanner used for acquisition, since, as 
shown in a previous study [32], the SPM single-subject procedure provides comparable results even when 
images are acquired with different scanners.  First, a voxel-wise map of commonalities was computed in order 
to evaluate the degree of overlap between the single-subject hypometabolism pattern in each dementia group, 
using the two new HC groups (AIMN-HC and ADNI-HC). The commonality value of each voxel in these 
commonality maps was computed as the proportion of patients in which that specific voxel was found to be 
hypometabolic. The resulting commonality maps were first visually inspected to evaluate their consistency 
with the topography of known hypometabolism patterns reported in the literature. Second, the t-maps obtained 
with the HSR-HC dataset (HSR SPM t-maps), representing the reference standard, were directly compared to 
t-maps obtained with the AIMN-HC and ADNI-HC datasets. To do so, after the single subject SPM procedure 
was run for each patient against the three HC dataset (HSR-HC, AIMN-HC and ADNI-HC), we assessed  
concordance between SPM t-maps obtained with the two HC datasets by means of Dice analysis. A Dice score 
for two binary images A and B is defined as: 
𝐷𝐼𝐶𝐸 =
2 ∗ (𝐴 ∩ 𝐵)
𝐴 + 𝐵
 
Where with 𝐴 ∩ 𝐵 we mean the number of elements present in the intersection between the two masks (i.e. 
voxels that are commonly hypometabolic in the two masks), and with 𝐴 + 𝐵 we mean the sum of all the 
elements in 𝐴 and 𝐵 (i.e. voxels that are hypometabolic in mask A and mask B).  Dice coefficient  takes the 
value of 1 if A and B assume the same logical value in every voxel (high concordance), and a value of 0 if they 
always disagree (null concordance). Basically, Dice scores represent the amount of spatial overlap of the 
identified brain hypometabolic regions in each single patient. Resulting Dice coefficients were then averaged 
over all patients to provide a summary measure of concordance in each cohort, when using AIMN-HC and 
ADNI-HC datasets for comparison. Further, a voxel-wise Dice map was computed over all patients, to measure 
how often both analyses agreed in each single voxel.   
We also performed Chi-squared tests to compare the accuracy values obtained by using the two different 
datasets. 
Sample size and statistical thresholds effects – We also assessed the comparability of the results of the SPM 
standardized single-subject procedure for each HC dataset, by changing the sample size of the HC dataset and 
the statistical thresholds applied for the SPM t-map extraction. Thus, we performed again our SPM 
standardized single-subject procedure considering for comparison a randomly subsampled pool of HC from 
the AIMN database (n=10, n=30, n=75, n=125), and for ADNI database (n=10, n=30, n=75). In the same 
analysis, we assessed how the HC group sample sizes and the use of different statistical thresholds and 
corrections (i.e. p<0.05 with Family-wise error correction, p<0.01 and p<0.05 uncorrected for multiple 




































































(ADD, DLB and bvFTD). We created three different binary masks, one representing the AD-like pattern, one 
representing the DLB-like pattern and one representing the bvFTD-like pattern. The masks were obtained by 
averaging the t-maps derived from SPM single-subject analysis for each clinical group and converting them 
into binary images. Then, we assessed the pattern expression for each patient by means of a voxel-wise 
comparison between binary masks and patient’s SPM t-maps. The pattern expression (PE) was defined with 





Where 𝑁𝑆𝑃𝐸𝐶  represents the number of voxels found to be hypometabolic within the prototypical mask and 
𝑁𝑚𝑎𝑠𝑘 represents the number of voxels of the prototypical mask.  
A rater-independent evaluation was obtained by classifying each pattern as AD, bvFTD or DLB-like according 
to the maximum level of similarity to the standardized binary mask prototypical for each condition (i.e. the 
highest PE).  Then, the rater-independent evaluation (AD-like, DLB-like, bvFTD-like pattern) was compared 
with the clinical diagnosis at follow-up (ADD, DLB or bvFTD diagnosis) in order to assess the classification 
accuracy of the SPM maps for each clinical condition.  
 
Results 
Selection of HC datasets 
The initial assessment excluded n=20 HC from the original n=187 subjects within the AIMN database. The 
excluded images had a resolution recovery algorithm for reconstruction incorporating correction of partial 
volume effect, which makes these images incomparable with the rest of the HC database [33]. Further,  
quantification with resolution recovery, on top of not being comparable with standard reconstruction, provides 
divergent results among vendors [34].  
In the first step, the Cook’s distance analysis identified n=23 outliers out of 167 subjects in the AIMN database 
and n=11 outliers out of 101 subjects in the ADNI database (D=0.0051 as critical value). The second-step 
analysis identified n=32 outliers out of 167 subjects in theAIMN database and n=12 outliers out of 101 subjects 
in theADNI database (setting D=0.0084 as critical value). Overall, the two steps voxel-wise quantitative 
outliers’ detection analyses resulted in the selection of n=135 for the AIMN and n=89 for the ADNI datasets, 
representative of the same normal distribution (Figure 1).  
Amongst the images included by means of Cook’s analysis, Jack-knife analysis and neuroimaging experts 
subsequently excluded those images showing hypometabolism clusters that, even if of limited extension, were 
deemed as pathological.  After this final analysis, n=125 HC subjects for AIMN and n=75 HC subjects for 
ADNI were evaluated as having normal [18F]FDG PET images. These subjects were included in the final HC 




































































In order to provide the scientific community with the 18F]FDG PET selected images, the list of codes (RID) 
of the HC subjects selected from ADNI are provided in Supplementary Table 1. 
 
Evaluation of HC datasets for t-maps extraction in dementia conditions 
The SPM single-subject procedure obtained by using the selected AIMN-HC and ADNI-HC groups for 
comparison yielded patterns of brain hypometabolism in the three groups of patients consistent with those 
reported in the literature [6,11,27,35–37]. Figure 2 and 3 (left panel) show the commonalities of SPM t-maps 
for the three clinical groups, obtained by using the AIMN dataset and the  ADNI dataset, respectively. 
Specifically, the commonalities of AD hypometabolism t-maps involved temporoparietal association cortices, 
the precuneus and posterior cingulate cortex, the DLB hypometabolism t-maps involved the lateral and medial 
occipital cortex, temporo-parietal and frontal cortex, bilaterally, whereas the bvFTD hypometabolism t-maps 
showed the involvement of the dorsolateral frontal cortex, the insula and temporal regions (see Fig. 2-3). 
When we compared the degree of overlap between hypometabolism patterns obtained with the new HC 
datasets (AIMN and ADNI) and the reference standard HSR-HC dataset, we obtained an average concordance 
of 0.87 in the AIMN-HSR comparison and 0.83 in the ADNI-HSR comparison. In the ADD clinical group, the 
AIMN-HSR concordance was 0.88 and 0.83 for the ADNI-HSR comparisons. For the DLB clinical group, we 
obtained an average concordance of 0.86 in the AIMN-HSR comparison and of 0.82 in the ADNI-HSR 
comparison. For the bvFTD clinical group, we obtained an average concordance of 0.89 in the AIMN-HSR 
comparison and of 0.86 in the ADNI-HSR comparison. In Figure 2 and 3 (right panel), we show the voxel-
wise maps of Dice scores, representing the agreement in resulting hypometabolism maps in the two analyses 
with different HC datasets. In the hallmark regions of hypometabolism, the agreement between SPM t-maps 
obtained with AIMN-HC and HSR-HC datasets was higher than 0.94 (ADD=0.96, DLB=0.95 and 
bvFTD=0.94) and equal to 0.93 in the ADNI-HSR comparison (ADD=0.93, DLB=0.94 and bvFTD=0.93). 
This indicates, at the voxel level, that the SPM statistical method obtained using different control databases 
produce hypometabolism SPM t-maps with very high levels of spatial concordance.  
Pattern expression analysis revealed that the number of voxels found to be statistically significant within the 
disease typical group-level maps increased proportionally with the number of HC subjects included in the 
single-subject SPM comparison (Supplementary Table 2-4 and Figure 5). Of note, the most stringent statistical 
threshold, namely p<0.05 with family-wise error correction, when using a small HC sample size, i.e. n=10 HC 
subjects, prevented us from obtaining any statistically significant result in all three groups of patients (PE=0). 
The highest pattern expression (PE=0.65) was achieved when n=125 subjects were used for comparison and 
p<0.05 uncorrected was applied as statistical threshold (Supplementary Table 2-4).     
An optimal accuracy (>80%) of the SPM t-map classification with respect to the clinical diagnosis was 
achieved when a large sample size (>30) was used, regardless of the statistical threshold applied (see Figure 4 




































































allowed to obtain hypometabolism voxel in hallmark regions, such as the hypometabolism in parietal cortex 
for AD, but prevented a full-blown pattern expression. This translated into a lower accuracy in the 
discrimination between conditions that present some overlap in their typical hypometabolism patterns, such as 
ADD and DLB. Accordingly, using a high statistical threshold, the DLB-like pattern reached a classification 
accuracy of ≈60-70%.  
The classification accuracy obtained with the two HC datasets did not show any statistically significant 
difference, namely performance of AIMN and ADNI HC datasets were equivalent (χ2 AD 0.05 unc=2.07, χ2 DLB 
0.05 unc=6.8, χ2 BvFTD 0.05 unc=1.8; χ2 AD 0.01 unc=0.9 χ2 DLB 0.01 unc=4.3 χ2 BvFTD 0.01 unc=2.1 ; χ2 AD 0.05 FWE=0.2 χ2 
DLB 0.05 FWE=4.7 χ2 BvFTD 0.05 FWE=3.1) 
 
Discussion 
Patients with different dementias may show partially overlapping clinical presentations, which prevents a 
proper clinical classification. The last decades have progressively witnessed a shift from a purely clinical 
diagnosis to a biomarker-supported diagnosis, and molecular neuroimaging techniques such as PET have 
played a leading role in the dementia research diagnostic work-up [6,10,11,38–40]. The ability to discriminate 
between different neurodegenerative conditions, together with the ability to detect a disease process even 
before the occurrence of clinical manifestations, has huge implications for diagnosis and prognosis in imaging  
research, clinical trials and therapeutic approaches. In the case of cerebral glucose metabolism, a large amount 
of literature has provided clear evidence of specific, disease-related [18F]FDG PET patterns [20,27,35,36,41–
43], which are significantly accurate and useful. Sensitive and specific [18F]FDG PET analysis tools for the 
detection of brain hypometabolism at single-subject level are crucial, particularly for the detection of specific, 
early brain metabolic changes. However, only methods employing parametric and voxel-based analysis 
techniques can provide unbiased, statistically defined measures of brain abnormality across the whole brain 
[44].  
The SPM single-subject standardized procedure presented in this study, allows the identification of disease-
specific brain hypometabolism patterns in single individuals with high statistical power [20]. Still, the ability 
to identify patterns of neurodegeneration with high sensitivity and specificity depends on specific operational 
standards. Among them, the use of internationally recognized control datasets (e.g. US ADNI, NEST-DD or 
the European Alzheimer’s Disease PET Consortium—EADC-PET) that include individuals who were 
acquired with standardized procedure and are clinically characterized so as to exclude cognitive deterioration, 
is recommended [44].   
In this study, we provided a step-by-step selection and validation of two healthy control [18F]FDG PET 
datasets that have been collected by two internationally recognized scientific associations (AIMN and ADNI). 
Standardized acquisition procedures for [18F]FDG PET imaging were applied with a high standard, with the 




































































data collection for longitudinal studies. Of note, these images were acquired with different PET scanners; 
however, the application of standardized acquisition procedures followed by appropriate post-processing 
provided reliable results. In a previous study  we demonstrated that the use of HC data acquired with different 
PET scanners shows no influence on the performance of standardized SPM procedures  [45].    
Here, by following several quality-control steps, we selected two subsets of HC subjects that provide 
comparable and very accurate results in the detection of brain metabolic patterns of neurodegeneration. 
First, we selected the subjects characterized by absence of global cognitive impairment, and we also considered 
cognitive stability after a 4-year clinical follow-up. Since early abnormalities in [18F]FDG PET scans are 
likely to affect regions characterized by very early pathological changes [46], inclusion of  subjects in 
preclinical phases in a cohort of HC would hamper statistical power, making detection of hypometabolism, 
especially in regions of crucial relevance for diagnostic and prognostic purposes, more biased. Moreover, for 
the ADNI-HC database, we excluded subjects showing cerebral amyloid retention at amyloid-PET.  
It must be noted that, while information on amyloid pathology and clinical follow-up was available only in the 
ADNI-HC dataset, we put into place a stringent analytical pipeline in both the AIMN-HC and ADNI-HC 
datasets, so as to ensure selection of only those HC subjects, with a brain [18F]FDG PET scan that clearly 
excluded ongoing dysfunctional changes. All these procedures hence allowed us to select only HC subjects 
with a negative [18F]FDG PET scan. To this regard, it is worth noting that  our rigorous analytical pipeline 
allowed us to select AIMN-HC and ADNI-HC datasets providing highly concordant results in the extraction 
of brain hypometabolism patterns as compared to the validated reference standard (close to 100% concordance 
in the most relevant hypometabolism hallmarks) and both yielding optimal (>80%) accuracy in discriminating 
among the three major dementing conditions. 
Age-related decreases of brain metabolism could characterize HC subjects. However, hypometabolism in HC 
does not follow the topographical distribution of the hypometabolism patterns related to neurodegenerative 
conditions. Age-related hypometabolism is more distributed, it may involve medial frontal cortex, and anterior 
cingulate cortex, but not with the severity and the extension in posterior brain regions or the dorsolateral frontal 
cortex as observed in patients with ND [47]. In order to select only those HC subjects with “normal” brain 
metabolism, we performed a quantitative data-driven outlier’s detection analysis, by means of Jack-Knife 
approach and Cook’s distance analysis (Figure 1). The two quantitative procedures allowed us to exclude HC 
subjects with levels of brain metabolism deviating from the normal distribution of the overall sample. 
Overall, the selection of HC subjects following different quality control steps allowed to obtain, in the 
comparison with three independent cohorts of patients, patterns of brain hypometabolism with high statistical 
power, yielding hypometabolism topographies that are clearly consistent with the literature (Figure 2-3 and 
Table 3-4). Accurate discrimination between dementing conditions was achieved both when considering the 




































































for comparison. This result further confirms the high similarity and internal consistency of the HC [18F]FDG 
PET images selected through the two-step analytical pipeline.  
It was previously reported that when random field theory is used in neuroimaging to estimate the number of 
multiple comparisons, as it is performed in SPM, the less degrees of freedom are used in the test, the more 
conservative this correction becomes [48]. This phenomenon is especially strong when less than 30 HC are 
present, as clearly shown in the present PE analysis (Supplementary Table 2 and Figure 3). This highlights the 
importance of using a proper number of HC for constructing a normal dataset. A high dataset numerosity 
ensures good statistical power to detect all the hypometabolic clusters of crucial diagnostic relevance, also 
when more conservative statistical thresholds are applied.  A previous study showed that diagnostic 
performance of [18F]FDG PET  in discriminating ADD patients from HC, as measured by receiver operating 
characteristic curve, was relatively poor when the sample size of the HC dataset was small (i.e. <10), possibly 
because of high statistical noise due to small sample size [49].  They affirmed that only large normal datasets 
(e.g. > 60) would yield lower statistical noise and more stable diagnostic performance. Nevertheless, the 
authors acknowledged that such a very large dataset is not easily available in many clinical settings. 
Accordingly, Gallivanone and colleagues showed that the use of a HC dataset >50 is critical when the 
[18F]FDG uptake of brain regions crucial for diagnosis of AD, is unclear at visual inspection of the tracer 
radioactivity distribution [50]. 
Of note, our data also highlighted that the use of a FWE strategy should be carefully considered, when the 
number of healthy controls available for comparison is less than 10. Note that the proposed standardized 
procedure using large and well-selected HC datasets, allows to obtain reliable patterns of brain 
hypometabolism in single individuals also when less conservative statistical thresholds are applied. The use of 
less conservative thresholds (e.g. 0.05 uncorrected) and/or larger HC sample size (>30) provides the maximum 
pattern expression (PE=0.65) without producing false negative values, i.e. voxel being significantly 
hypometabolic but not belonging to the prototypical hypometabolism pattern (Figure 4). 
The extraction of reliable and informative hypometabolism pattern is particularly relevant in supporting 
differential diagnosis in conditions characterized by partially overlapping hypometabolism patterns, such as 
ADD and DLB. A full-blown pattern expression allows to obtain more information, that may be crucial to 
obtain a correct diagnosis for the clinician. In this regard, in a previous study, we demonstrated that the 
presence of an occipital lobe hypometabolism yields great ability to discriminate between DLB and ADD [36]. 
The use of a standardized approach, allowing the extraction of early brain dysfunctional changes at the single-
subject level, predating a full-blow expression of dementia, improves diagnosis in prodromal disease phases,  
such as in mild cognitive impairment, avoiding multiple clinical and instrumental examinations over months 
and years [51]. 
In conclusion, in this study we describe the performance of two large, well-selected HC datasets from a 
European and American database, respectively. These HC datasets, selected through a stringent two-step 




































































assessment. The HC datasets described in the current study are ready-to-use, and the analytical pipeline here 
described might be helpful to other research centres, promoting the quality and reliability of brain metabolism 
estimation for the wide clinical and research community. 
Information Sharing Statement 
We will make available the HC datasets to the whole research and clinical community. All ADNI data are 
shared without embargo through the LONI Image and Data Archive (IDA), a secure research data repository. 
Interested scientists may obtain access to ADNI imaging, clinical, genomic, and biomarker data for the 
purposes of scientific investigation, teaching, or planning clinical research studies. Details about the ADNI-
HC subjects selected for this study are reported in the Supplementary Material, Table 1. For those researchers 
who intend to use the ADNI-HC imaging database for their studies, it is recommended to follow the full pre-
and post-processing procedures presented in the current paper in order to obtain comparable results. 
The AIMN-HC dataset will be soon available on the SPM official website http://www.fil.ion.ucl.ac.uk/spm/ 
through the following URL: https://dorian.ge.infn.it/.  
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Table 1. Descriptive statistics of the selected healthy controls in the HSR, AIMN and ADNI datasets. 
 HSR-HC AIMN-HC ADNI-HC 
N 112 125 75 
Sex (M/F), N 53/59 58/67 33/42 
Age, mean±SD 64.68±9.34 65.78±11.33 72.25±5.25 
Education, mean±SD - 10.5±4.29 16.60±2.48 
MMSE, mean±SD - 28.75±1.69 28.97±1.40 
 
 
Table 2. Descriptive statistics of the patient groups 
 Probable ADD Probable DLB bvFTD 
N 79 81 56 
Sex (M/F), N 32/47 27/29 43/38 
Age, mean±SD 67.58±7.51 72.10±7.60 69.41±7.67 
Education, 
mean±SD 
11.83±6.96 9.44±4.52 9.00±5.66 
MMSE, mean±SD 18.80±3.65 17.54±4.47 19.77±6.67 
 
Table 3. Statistical accuracy of the SPM t- hypometabolism maps to correctly classify clinical diagnosis 
for different HC-AIMN sample sizes and statistical thresholds. 
  p<0.05, Uncorrected p<0.01, Uncorrected p<0.05, FWE-corrected 
  n=10 n=30 n=75 n=125 n=10 n=30 n=75 n=125 n=10 n=30 n=75 n=125 
ADD 87% 89% 90% 92% 83% 88% 87% 88% 0% 95% 90% 88% 
DLB 81% 87% 85% 85% 78% 83% 81% 81% 0% 62% 69% 68% 
bvFTD 93% 94% 93% 93% 93% 93% 93% 92% 0% 85% 88% 88% 
Total 87% 90% 89% 90% 85% 88% 87% 87% 0% 80% 82% 81% 
 
Abbreviations: ADD, Alzheimer’s disease dementia; DLB, dementia with Lewy body; bvFTD, behavioural 
variant of frontotemporal dementia; FWE, family-wise error correction. 
 
Table 4. Statistical accuracy of the SPM t- hypometabolism maps to correctly classify clinical diagnosis 
for different HC-ADNI sample sizes and statistical thresholds.  
 p<0.05, uncorrected p<0.01, uncorrected p<0.05, FWE-corrected 
  n=10 n=30 n=75 n=10 n=30 n=75 n=10 n=30 n=75 
ADD 95% 95% 95% 92% 94% 90% 0% 93% 87% 
DLB 86% 88% 88% 85% 87% 85% 0% 63% 63% 
bvFTD 92% 92% 93% 91% 91% 94% 0% 88% 89% 





































































Abbreviations: ADD, Alzheimer’s disease dementia; DLB, dementia with Lewy body; bvFTD, behavioural 










Figure 1. Scatter plot of the two steps Cook’s distance analysis.  
Outliers (red dots) are represented by [18F]FDG PET images with larger Cook’s distance values than the 
critical D value. The analysis was performed separately for both AIMN-HC and ADNI-HC datasets (upper 







































































Figure 2. Voxel-wise maps of hypometabolism commonalities and concordance (AIMN-HC dataset).  
Left column: commonalities of the SPM t-maps in ADD, DLB and bvFTD groups. The value of each voxel 
represents the proportion of patients, in each group, presenting with hypometabolism in that voxel, as 
estimated from the comparison with the AIMN-HC dataset. Commonality maps are fairly consistent with the 
known patterns of hypometabolism in each dementing condition. Only voxels with a commonality>0.30 are 
shown, for visualization purposes. 
Right column: concordance between SPM t-maps in ADD, DLB and bvFTD groups. The value of each voxel 
represents the average amount of spatial overlap between single-subjects hypometabolism maps, as estimated 
from the comparison with the AIMN-HC dataset, vs. single-subjects hypometabolism maps estimated from 






































































Figure 3. Voxel-wise maps of hypometabolism commonalities and concordance (ADNI-HC dataset).  
Left column: commonalities of the SPM t-maps in ADD, DLB and bvFTD groups. The value of each voxel 
represents the proportion of patients, in each group, presenting with hypometabolism in that voxel, as 
estimated from the comparison with the ADNI-HC dataset. Commonality maps are fairly consistent with the 
known patterns of hypometabolism in each dementing condition. Only voxels with a commonality>0.30 are 
shown, for visualization purposes. 
Right column: concordance between SPM t-maps in ADD, DLB and bvFTD groups. The value of each voxel 
represents the average amount of spatial overlap between single-subject hypometabolism maps, as estimated 
from the comparison with the ADNI-HC dataset, vs. single-subjects hypometabolism maps estimated from 







































































Figure 4. Receiver Operating Characteristic (ROC) curves. ROC curves comparing diagnostic 
performance of SPM t-maps using normal database with different sample sizes (10, 30, 75, 125) and different 
statistical thresholds and corrections ( p<0.05 uncorrected, p<0.01 uncorrected and p<0.05 FWE-corrected) 









































































Figure 5. Pattern expression in the ADD group when different statistical thresholds and HC sample 
sizes are  applied for the extraction of SPM single-subject hypometabolism maps. Panel A and B shows 
results obtained when considering the AIMN-HC dataset and  the ADNI-HC datasets for the SPM single-
subject analysis, respectively. Brain renderings of group-level hypometabolism maps at different thresholds 
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